NasdaqGS - Delayed Quote USD

United Therapeutics Corporation (UTHR)

237.93 +1.00 (+0.42%)
At close: 4:00 PM EDT
237.93 0.00 (0.00%)
After hours: 5:11 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,327,500.00
2,327,500.00
1,936,300.00
1,685,500.00
1,483,300.00
Cost of Revenue
257,500.00
257,500.00
151,600.00
122,500.00
108,100.00
Gross Profit
2,070,000.00
2,070,000.00
1,784,700.00
1,563,000.00
1,375,200.00
Operating Expense
885,100.00
885,100.00
805,000.00
1,007,100.00
781,600.00
Operating Income
1,184,900.00
1,184,900.00
979,700.00
555,900.00
593,600.00
Net Non Operating Interest Income Expense
103,400.00
103,400.00
12,800.00
-1,900.00
5,100.00
Other Income Expense
-14,000.00
-14,000.00
-41,900.00
39,900.00
40,200.00
Pretax Income
1,274,300.00
1,274,300.00
950,600.00
593,900.00
638,900.00
Tax Provision
289,500.00
289,500.00
223,300.00
118,100.00
124,100.00
Net Income Common Stockholders
984,800.00
984,800.00
727,300.00
475,800.00
514,800.00
Diluted NI Available to Com Stockholders
984,800.00
984,800.00
727,300.00
475,800.00
514,800.00
Basic EPS
19.28
21.04
15.98
10.60
11.65
Diluted EPS
18.13
19.81
15.00
10.06
11.54
Basic Average Shares
46,550.00
46,800.00
45,500.00
44,900.00
44,200.00
Diluted Average Shares
49,550.00
49,700.00
48,500.00
47,300.00
44,600.00
Total Operating Income as Reported
1,184,900.00
1,184,900.00
979,700.00
555,900.00
593,600.00
Total Expenses
1,142,600.00
1,142,600.00
956,600.00
1,129,600.00
889,700.00
Net Income from Continuing & Discontinued Operation
984,800.00
984,800.00
727,300.00
475,800.00
514,800.00
Normalized Income
984,800.00
984,800.00
728,609.00
477,640.00
522,171.00
Interest Income
162,700.00
162,700.00
45,200.00
16,700.00
28,600.00
Interest Expense
59,300.00
59,300.00
32,400.00
18,600.00
23,500.00
Net Interest Income
103,400.00
103,400.00
12,800.00
-1,900.00
5,100.00
EBIT
1,333,600.00
1,333,600.00
983,000.00
612,500.00
662,400.00
EBITDA
1,386,800.00
1,386,800.00
1,034,300.00
662,400.00
712,300.00
Reconciled Cost of Revenue
257,500.00
257,500.00
151,600.00
122,500.00
108,100.00
Reconciled Depreciation
53,200.00
53,200.00
51,300.00
49,900.00
49,900.00
Net Income from Continuing Operation Net Minority Interest
984,800.00
984,800.00
727,300.00
475,800.00
514,800.00
Total Unusual Items Excluding Goodwill
--
--
-1,700.00
-2,300.00
-9,100.00
Total Unusual Items
--
--
-1,700.00
-2,300.00
-9,100.00
Normalized EBITDA
1,386,800.00
1,386,800.00
1,036,000.00
664,700.00
721,400.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-391.00
-460.00
-1,729.00
12/31/2020 - 6/17/1999
Yahoo Finance Plus Essential access required. Unlock Access

Related Tickers

LQDA Liquidia Corporation
13.29
-3.77%
 
MNKD MannKind Corporation
4.1800
+2.45%
 
INCY Incyte Corporation
52.35
-0.89%
 
HALO Halozyme Therapeutics, Inc.
38.64
+2.20%
 
HRMY Harmony Biosciences Holdings, Inc.
29.40
+1.27%
 
ARGX argenx SE
360.23
+0.51%
 
BMRN BioMarin Pharmaceutical Inc.
88.63
-1.60%
 
JAZZ Jazz Pharmaceuticals plc
109.94
+0.61%
 
BPMC Blueprint Medicines Corporation
86.85
-2.31%
 
ALNY Alnylam Pharmaceuticals, Inc.
144.41
-0.52%